Pharmaceutical excipients are the collective term for all materials added to a formulation except the main drug to address the formability, effectiveness, stability, and safety of the preparation. Their reliable quality and diversity are fundamental to ensuring the advancement of dosage forms and preparations. Excipients and auxiliary materials used in pharmaceutical production and pharmaceutical excipient formulations are substances that have undergone reasonable safety evaluations, including those in pharmaceutical preparations, in addition to the active ingredients. In addition to shaping, acting as carriers, and improving stability, pharmaceutical excipients also have important functions such as solubilization, cosolvency, and controlled release.

With the development of China's pharmaceutical industry, pharmaceutical excipients have also seen significant growth. In 2018, the market size of pharmaceutical excipients in China reached 183.501 billion yuan, an increase of 15.56% year-on-year, with a significant increase in the variety of preparations. New dosage forms that could not be produced domestically in the past have begun mass production, and the development and production of pharmaceutical excipients have made significant progress. The former State Administration of Medical Politics and Pharmaceutical Industry also attaches great importance to the development of pharmaceutical excipients. A "National Pharmaceutical Excipients Academic Seminar" is held every two years, effectively promoting the development and application of new excipients, and significantly improving the quality of some pharmaceutical products. However, nationwide, China's excipient development is relatively late and still requires technological upgrades and structural adjustments to meet the needs of domestic pharmaceutical production development and exports.

The impact of medical and health system reform: The medical and health system reform has expanded the beneficiary groups and the degree of benefits of drug security, promoting the rapid growth of the pharmaceutical industry. In the medical and health system reform, the basic drug bidding system, coupled with the drug bidding system implemented in previous years, has formed a medical institution drug procurement mechanism dominated by price competition. Although the national price management department has formulated a sound price policy to improve drug quality and reduce the use of sucrose, due to a lack of corresponding technology, including a lack of better pharmaceutical excipients, most pharmaceutical companies are still trapped in homogeneous competition